Division of Pulmonary and Critical Care Medicine, Department of Medicine, Temple University School of Medicine, Philadelphia, PA, USA.
Int J Chron Obstruct Pulmon Dis. 2014 Jan 24;9:139-50. doi: 10.2147/COPD.S38938. eCollection 2014.
Airway mucus is part of the lung's native immune function that traps particulates and microorganisms, enabling their clearance from the lung by ciliary transport and cough. Mucus hypersecretion and chronic productive cough are the features of the chronic bronchitis and chronic obstructive pulmonary disease (COPD). Overproduction and hypersecretion by goblet cells and the decreased elimination of mucus are the primary mechanisms responsible for excessive mucus in chronic bronchitis. Mucus accumulation in COPD patients affects several important outcomes such as lung function, health-related quality of life, COPD exacerbations, hospitalizations, and mortality. Nonpharmacologic options for the treatment of mucus accumulation in COPD are smoking cessation and physical measures used to promote mucus clearance. Pharmacologic therapies include expectorants, mucolytics, methylxanthines, beta-adrenergic receptor agonists, anticholinergics, glucocorticoids, phosphodiesterase-4 inhibitors, antioxidants, and antibiotics.
气道黏液是肺固有免疫功能的一部分,可捕获颗粒物和微生物,并通过纤毛运动和咳嗽将其从肺部清除。黏液过度分泌和慢性咳痰是慢性支气管炎和慢性阻塞性肺疾病(COPD)的特征。杯状细胞的过度产生和分泌以及黏液清除减少是导致慢性支气管炎中黏液过多的主要机制。COPD 患者的黏液积聚会影响多个重要结果,如肺功能、健康相关生活质量、COPD 加重、住院和死亡率。COPD 中黏液积聚的非药物治疗选择包括戒烟和用于促进黏液清除的物理措施。药物治疗包括祛痰剂、黏液溶解剂、黄嘌呤类药物、β肾上腺素能受体激动剂、抗胆碱能药物、糖皮质激素、磷酸二酯酶-4 抑制剂、抗氧化剂和抗生素。